Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

Background Pembrolizumab has shown improved progression-free survival versus
chemotherapy in patients with newly diagnosed microsatellite instability-high or mismatch …

Myeloid cells are pivotal within the immunosuppressive tumour microenvironment. The
accumulation of tumour-modified myeloid cells derived from monocytes or neutrophils …

Immunotherapy has revolutionized cancer treatment and substantially improved patient
outcome with regard to multiple tumour types. However, most patients still do not benefit …

Since the discovery of Stimulator of Interferon Genes (STING) as an important pivot for
cytosolic DNA sensation and interferon (IFN) induction, intensive efforts have been …

Sequence alterations in microsatellites and an elevated mutational burden are observed in
20% of gastric cancers and associated with clinical response to anti–PD-1 antibodies …

Immune checkpoint blockade (ICB) immunotherapy is a first-line treatment for selected
cancers, yet the mechanisms of its efficacy remain incompletely understood. Furthermore …

Tumors with defective mismatch repair (dMMR) are responsive to immunotherapy because
of dMMR-induced neoantigens and activation of the cGAS-STING pathway. While …

KRAS-LKB1 (KL) mutant lung cancers silence STING owing to intrinsic mitochondrial
dysfunction, resulting in T cell exclusion and resistance to programmed cell death (ligand) 1 …